Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15008222 | 0.85 | MEN1 (0.41) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL19223871 | 0.85 | MEN1 (0.41) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL15243991 | 0.85 | MEN1 (0.41) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL15243990 | 0.80 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL15508809 | 0.77 | MET (0.44) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL21167338 | 0.77 | MET (0.44) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL20519517 | 0.77 | MET (0.44) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL299606 | 0.77 | MET (0.44) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL8297005 | 0.77 | MET (0.44) | L3MBTL1MEN1KMT2AKDM4CMET | |
| SCHEMBL20247028 | 0.77 | MET (0.43) | L3MBTL1MEN1KMT2AKDM4CMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| WO-2021250194-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | L3MBTL1 4833/4885MEN1 2872/4885KMT2A 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.